We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.50 | 0.37% | 1,780.00 | 1,779.50 | 1,780.50 | 1,786.50 | 1,771.50 | 1,780.00 | 2,025,557 | 13:41:55 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.90 | 73.43B |
From May 2019 to May 2024
TIDMGSK
RNS Number : 1709N
GlaxoSmithKline PLC
15 January 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
Hot Features
Premium
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Ms E Walmsley
=== ======================== ================================================
b) Position/status Chief Executive Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 19 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 10 January 2019
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.3600 199
----------
GBP15.3600 216
----------
GBP15.3600 758
----------
GBP15.3600 199
----------
GBP15.3600 216
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
1,588
GBP15.3600
=== ======================== ================================================
e) Date of the transaction 2019-01-11
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Mr R G Connor
=== ========================= ==============================================
b) Position/status President, Global Vaccines
=== ========================= ==============================================
c) Initial notification/ Initial notification
amendment
=== ========================= ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ========================= ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ========================= ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary shares of 19 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ========================= ==============================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of
dividends paid to shareholders on 10 January
2019 on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ========================= ==============================================
c) Price(s) and volume(s) Price(s) Volume(s)
----------
GBP15.3600 135
----------
GBP15.3600 113
----------
GBP15.3600 161
----------
GBP15.3600 113
----------
=== ========================= ==============================================
d) Aggregated information
Aggregated volume
Price
522
GBP15.3600
=== ========================= ==============================================
e) Date of the transaction 2019-01-11
=== ========================= ==============================================
f) Place of the transaction London Stock Exchange (XLON)
=== ========================= ==============================================
1. Details of PDMR/person closely associated with them ('PCA')
==========================================================================
a) Name Mr S P Dingemans
=== ======================== ================================================
b) Position/status Chief Financial Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 19 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 10 January 2019
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.3600 263
----------
GBP15.3600 197
----------
GBP15.3600 537
----------
GBP15.3600 263
----------
GBP15.3600 197
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
1,457
GBP15.3600
=== ======================== ================================================
e) Date of the transaction 2019-01-11
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr N Hirons
=== ======================== ================================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 19 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 10 January 2019
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.3600 97
----------
GBP15.3600 71
----------
GBP15.3600 84
----------
GBP15.3600 97
----------
GBP15.3600 71
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
420
GBP15.3600
=== ======================== ================================================
e) Date of the transaction 2019-01-11
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Mr B McNamara
==== ========================= ==============================================
b) Position/status CEO, GSK Consumer Healthcare
==== ========================= ==============================================
c) Initial notification/ Initial notification
amendment
==== ========================= ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================
a) Name GlaxoSmithKline plc
==== ========================= ==============================================
b) LEI 5493000HZTVUYLO1D793
==== ========================= ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ========================= ==============================================
b) Nature of the Increase in notional interest in American
transaction Depository Shares following the re-investment
of dividends paid to shareholders on 10
January 2019 on American Depository Shares
held in the Company's Deferred Annual Bonus
Plan.
==== ========================= ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 39.3600 82
----------
$ 39.3600 80
----------
==== ========================= ==============================================
d) Aggregated information
Aggregated volume
Price
162
$39.3600
============================== ==============================================
e) Date of the transaction 2019-01-11
==== ========================= ==============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ========================= ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr L Miels
=== ======================== ================================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 19 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 10 January 2019
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.3600 153
----------
=== ======================== ================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ================================================
e) Date of the transaction 2019-01-11
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr D Redfern
=== ======================== ================================================
b) Position/status Chief Strategy Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 19 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 10 January 2019
on Ordinary Shares held in the Company's
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.3600 124
----------
GBP15.3600 90
----------
GBP15.3600 156
----------
GBP15.3600 124
----------
GBP15.3600 90
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
584
GBP15.3600
=== ======================== ================================================
e) Date of the transaction 2019-01-11
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
========================================================================
a) Name Ms K Terrell
=== ======================== ==============================================
b) Position/status Chief Digital & Technology Officer
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ==============================================
b) Nature of the Increase in notional interest in American
transaction Depository Shares following the re-investment
of dividends paid to shareholders on 10
January 2019 on American Depository Shares
held in the Company's Deferred Annual Bonus
Plan.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 39.3600 27
----------
=== ======================== ==============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ==============================================
e) Date of the transaction 2019-01-11
=== ======================== ==============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Ms C Thomas
=== ========================= ==============================================
b) Position/status SVP, Human Resources
=== ========================= ==============================================
c) Initial notification/ Initial notification
amendment
=== ========================= ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ========================= ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ========================= ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary shares of 19 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ========================= ==============================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of
dividends paid to shareholders on 10 January
2019 on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ========================= ==============================================
c) Price(s) and volume(s) Price(s) Volume(s)
----------
GBP15.3600 181
----------
GBP15.3600 135
----------
GBP15.3600 170
----------
GBP15.3600 181
----------
GBP15.3600 135
----------
=== ========================= ==============================================
d) Aggregated information
Aggregated volume
Price
802
GBP15.3600
=== ========================= ==============================================
e) Date of the 2019-01-11
transaction
=== ========================= ==============================================
f) Place of the transaction London Stock Exchange (XLON)
=== ========================= ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr P C Thomson
=== ======================== ================================================
b) Position/status President, Global Affairs
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 19 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 10 January 2019
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.3600 111
----------
GBP15.3600 85
----------
GBP15.3600 106
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
302
GBP15.3600
=== ======================== ================================================
e) Date of the transaction 2019-01-11
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHZELFFKFFEBBX
(END) Dow Jones Newswires
January 15, 2019 09:56 ET (14:56 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
